AstraZeneca, Merck herald PhIII prostate cancer win for Lynparza — overtaking Clovis,...

cafead

Administrator
Staff member
  • cafead   Aug 07, 2019 at 10:52: AM
via The case for expanding Lynparza’s use just got stronger as AstraZeneca and Merck claim a late-stage success in extending the time prostate cancer patients live without progressing compared to standard of care.

article source